Highlights
KLSE: KOSSAN (7153)       KOSSAN RUBBER INDUSTRIES BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
6.18   -0.02 (0.32%)  6.15 - 6.25  1,924,200
Analyze this stock with MQ Trader system

Financials


Market Cap: 15,808 Million

Market Cap 15,808 Million
NOSH 2,558 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 10-Jun-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 10-Jun-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 09-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 21-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   166.10%  |    609.18%

Annual (Unaudited) ( EPS: 8.79, P/E: 70.32 )

Revenue | NP to SH 2,221,607  |  224,783
RPS | P/RPS 86.85 Cent  |  7.12
EPS | P/E | EY 8.79 Cent  |  70.32  |  1.42%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.56  |  11.14
YoY   11.95%
NP Margin | ROE 10.26%  |  15.83%
F.Y. | Ann. Date 31-Dec-2019  |  21-Feb-2020

T4Q Result ( EPS: 23.68, P/E: 26.10 )

Revenue | NP to SH 2,924,841  |  605,604
RPS | P/RPS 114.35 Cent  |  5.40
EPS | P/E | EY 23.68 Cent  |  26.10  |  3.83%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.75  |  8.20
QoQ | YoY   97.89%  |    171.21%
NP Margin | ROE 20.87%  |  31.42%
F.Y. | Ann. Date 30-Sep-2020  |  09-Nov-2020

Annualized Result ( EPS: 28.39, P/E: 21.77 )

Revenue | NP to SH 3,128,656  |  726,136
RPS | P/RPS 122.31 Cent  |  5.05
EPS | P/E | EY 28.39 Cent  |  21.77  |  4.59%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   85.37%  |    232.52%
NP Margin | ROE 23.43%  |  37.67%
F.Y. | Ann. Date 30-Sep-2020  |  09-Nov-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
T4Q 09-Nov-2020 30-Sep-2020 3 2,924,841 752,042 610,364 605,604 0 1,927,612 - % 20.87% 31.42% 1,278,936 228.69 114.35 47.35 23.68 0.00 0.00 1.5072 0.75   169.40% 30-Sep-2020 13.68 5.98 28.89 9.08 3.46% 0.00% 09-Nov-2020 7.50 3.28 15.84 4.98 6.31% 0.00%
31-Dec-2019 21-Feb-2020 31-Dec-2019 4 2,221,607 280,107 227,922 224,783 - 1,419,618 - % 10.26% 15.83% 1,278,936 173.71 86.85 17.58 8.79 0.00 0.00 1.1100 0.56   11.95% 31-Dec-2019 4.16 2.39 23.67 3.75 4.22% 0.00% 21-Feb-2020 4.65 2.68 26.46 4.19 3.78% 0.00%
31-Dec-2018 19-Feb-2019 31-Dec-2018 4 2,144,235 249,329 205,300 200,784 - 1,291,725 - % 9.57% 15.54% 1,278,936 167.66 83.83 15.70 7.85 0.00 0.00 1.0100 0.50   8.19% 31-Dec-2018 4.34 2.59 27.64 4.30 3.62% 0.00% 19-Feb-2019 4.00 2.39 25.48 3.96 3.92% 0.00%
31-Dec-2017 22-Feb-2018 31-Dec-2017 4 1,957,445 229,606 185,583 185,583 - 1,151,042 - % 9.48% 16.12% 639,468 306.11 76.53 28.77 7.26 0.00 0.00 1.8000 0.45   7.90% 29-Dec-2017 8.11 2.65 27.94 4.51 3.58% 0.00% 22-Feb-2018 8.70 2.84 29.98 4.83 3.34% 0.00%
31-Dec-2016 23-Feb-2017 31-Dec-2016 4 1,667,996 210,008 171,048 172,003 - 104,234,019 - % 10.25% 0.17% 639,472 260.84 65.21 26.13 6.72 0.00 0.00 163.0000 40.75   -15.07% 30-Dec-2016 6.59 2.53 24.50 0.04 4.08% 0.00% 23-Feb-2017 6.48 2.48 24.09 0.04 4.15% 0.00%
31-Dec-2015 23-Feb-2016 31-Dec-2015 4 1,639,509 268,567 206,319 202,530 35,170 946,412 17.37% 12.58% 21.40% 639,468 256.39 64.10 31.67 7.92 5.50 1.37 1.4800 0.37   39.10% 31-Dec-2015 9.30 3.63 29.36 6.28 3.41% 0.59% 23-Feb-2016 6.75 2.63 21.31 4.56 4.69% 0.81%
31-Dec-2014 25-Feb-2015 31-Dec-2014 4 1,301,740 186,721 148,836 145,597 - 799,393 - % 11.43% 18.21% 639,515 203.55 50.89 22.77 5.69 0.00 0.00 1.2500 0.31   6.73% 31-Dec-2014 4.47 2.20 19.63 3.58 5.09% 0.00% 25-Feb-2015 5.50 2.70 24.16 4.40 4.14% 0.00%
31-Dec-2013 26-Feb-2014 31-Dec-2013 4 1,307,292 180,134 140,055 136,422 44,771 697,148 32.82% 10.71% 19.57% 639,586 204.40 51.11 21.33 5.33 7.00 1.75 1.0900 0.27   33.53% 31-Dec-2013 4.32 2.11 20.25 3.96 4.94% 1.62% 26-Feb-2014 4.56 2.23 21.38 4.18 4.68% 1.54%
31-Dec-2012 25-Feb-2013 31-Dec-2012 4 1,234,001 138,451 104,772 102,163 12,788 60,107,637 12.52% 8.49% 0.17% 319,721 385.96 48.24 15.98 3.99 4.00 0.50 188.0000 23.50   13.91% 31-Dec-2012 3.36 0.87 10.52 0.02 9.51% 1.19% 25-Feb-2013 3.28 0.85 10.26 0.02 9.74% 1.22%
31-Dec-2011 24-Feb-2012 31-Dec-2011 4 1,089,969 112,920 91,081 89,684 35,783 546,511 39.90% 8.36% 16.41% 325,304 335.06 42.61 28.05 3.51 11.00 1.40 1.6800 0.21   -21.17% 30-Dec-2011 3.25 0.97 11.79 1.93 8.48% 3.38% 24-Feb-2012 3.28 0.98 11.90 1.95 8.41% 3.35%
31-Dec-2010 23-Feb-2011 31-Dec-2010 4 1,046,887 140,651 113,764 113,764 - 442,787 - % 10.87% 25.69% 320,860 326.27 40.93 35.46 4.45 0.00 0.00 1.3800 0.17   68.95% 30-Dec-2010 3.16 0.97 8.91 2.29 11.22% 0.00% 23-Feb-2011 3.18 0.97 8.97 2.30 11.15% 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock with T+7 trading account. Find out more.
  13 people like this.
 
Goku88 https://nypost.com/2020/11/24/moderna-boss-says-covid-shot-not-proven-to-stop-virus-spread/
26/11/2020 2:11 PM
Goku88 Moderna boss says COVID-19 vaccine not proven to stop spread of virus

Moderna’s coronavirus vaccine may not get life back to normal right away because it hasn’t yet been proven to prevent the deadly bug from spreading, the company’s top doctor says.
26/11/2020 2:11 PM
Kossan Fresh from NY times

Research has shown that the biotech firm’s shot is effective at preventing people from getting sick with COVID-19, but there’s no hard evidence that it stops them from carrying the virus “transiently” and potentially infecting others who haven’t been vaccinated, according to Dr. Tal Zaks, Moderna’s chief medical officer.
26/11/2020 3:04 PM
Kossan Fresh from Reuters

Gloves manufacturing companies in Malaysia is expecting skyrocketing earnings upside to the FY21 estimates due to global shortages of gloves amid closure of world’s largest glove producer, Top Gloves factories. The glove ASP may continue daily doubling rise until reopening. Previous analysts FY21 earnings may be underestimated.
26/11/2020 3:38 PM
Kossan Fresh from Bloomberg

Gloves manufacturers raised average selling prices (ASPs) of its gloves by another 40 per cent on a day-on-day basis due to partial closure of Top Gloves factories.

Business insiders said further ASP revisions were expected in the coming days as countries are gearing for mass vaccination program. Gloves security is a new terminology created and widely used by government officials. With the steep ASP hike projected, a spectacular earnings are expected for gloves producers.
26/11/2020 3:47 PM
Goku88 Supermx + TG already flying, time to hop into Kossan and ready to fly.
26/11/2020 4:17 PM
Goku88 https://www.nst.com.my/business/2020/11/644112/top-glove-tumbles-plant-closure-move-may-push-glove-prices-higher
26/11/2020 4:18 PM
Goku88 Top Glove tumbles on plant closure, move may push glove prices higher
26/11/2020 4:18 PM
Kossan Fresh from CNBC

After observing the steep rise in ASP a week go and onwards while the ASP is projected to skyrocket to a new level, our assumptions, we project Nov’20 ASP to increase by 50% and 60% in the following month before decreasing to 20% in FY21.

This is based on the assumption of a significant growth in ASP due to unprecedented closure of a leading glove manufacturer, Top Gloves which controls 25% of global market share. The elevated ASP will sustain into the first half of 2022 before moderating in FY23.

The earnings upside to the FY20 estimates would be high if Top gloves factories remain close for another week, which would suggest that the non- Top gloves counters may continue to rise and the precious FY20 earnings may be underestimated.
26/11/2020 7:09 PM
speakup https://www.malaymail.com/news/what-you-think/2020/11/25/case-for-windfall-taxes-lim-wei-jiet/1925899

WINDFALL TAX again?
26/11/2020 10:57 PM
Ukga Hope steep rise in ASP will reflect into higher share prices and better dividends payout in the future.... Cheers and Stay safe.
26/11/2020 11:22 PM
Kossan Fresh from Bloomberg

Non- Top gloves companies are expected to raise average selling prices (ASPs) of its gloves by another 50 per cent on a month-on-month basis.

An investment banker said some ASP still lagged behind some of its peers and further ASP upward revisions were expected in the coming days as it continued narrowing the pricing gap.
27/11/2020 9:22 AM
Kossan Fresh from Reuters

Rubber glove stocks under our coverage have gone through share price volatility over the past months on concerns that investors are looking at earnings beyond FY21. Based on our analysis presented in this report, we can conclude that: (i) ASP is going to be stubbornly high at least till mid 2022 which supports exponential QoQ earnings growth over the next few quarters, (ii) tight supply situation due to unprecedented closure of Top Glove factories following nitrile raw material and glove formers shortage will lead to longer production lead time, and (iii) 2020 to 2022 estimated incoming capacity are indicating demand to continue outpacing supply. All in, we are excited with the sector prospects over the next few quarters due to supply tightness amid strong demand. Specifically, industry trend of rising weekly and monthly ASPs is expected to boost bottom-lines. Amplifying the growth are restocking and inventory-building activities creating a supernormal demand spurt leading to acute supply shortage, due to the prolonged pandemic.
27/11/2020 11:22 AM
koolset Surgical glove makers struggle to keep pace with booming demand.

https://klse.i3investor.com/blogs/rubberglove_y2023/2020-11-27-story-h1536646457-Surgical_glove_makers_struggle_to_keep_pace_with_booming_demand.jsp
27/11/2020 1:58 PM
Mansonguitar why kossan always up so slow but drop so damn fast.. haih
27/11/2020 3:42 PM
Pgraduate123 Illegitimate child of the top 4 family
27/11/2020 4:11 PM
Eatshit76 Palia punya counter. Drop faster than others. Raise slower than others
27/11/2020 4:20 PM
speakup https://worldofbuzz.com/just-make-the-factory-look-closed-top-glove-employee-says-factory-still-operating-secretly/
our PN govt will fine Topglove kaw kaw for trying to cheat govt
27/11/2020 5:42 PM
Pgraduate123 Fined kossan too for being a cacat boy in the family... People party in the house, and he hide at one corner.
27/11/2020 8:13 PM
OngKawKaw MACAM NI TERUS SEND EMAIL TO PN GOVT LOL. BLOW JOBS KAT SINI TAK ADA ORANG DENGAR ONE MAH
27/11/2020 9:13 PM
OngKawKaw ATAU SENDIRI JADI GOVERNMENT LAH LAGI CIPAT
27/11/2020 9:14 PM
SaveMsiaFromPHGov Posted by gohkimhock > Nov 27, 2020 11:09 PM | Report Abuse

Should have use the share buyback money to upgrade the living conditions of their foreign workers. United States was right to ban them. A good company always treats its employees as asset.

====================

They spent about 1 bil already for sbb

If they can manage to sell back quietly quietly later at 25% gain when market is better, which is quite possible becos of glove stock price volatility, then they make 250 mil easy gain

They can do a lot of things with that 250 mil, including improving worker welfare

Can you understand this simple standard 3 maths?

Maybe you don't, becos you're the type of wacko cracko stuppid morron iddiot dikkhedd panicking monkey gang guy who would be throwing running at low, instead of wisely buying grabbing at low

So you reckon a company that has made qrtr pat 1.29 bil (next qrtr pat likely 2+ bil) has little clue about what it needs to do?

Go fukk yourself, smart arse hot shot
28/11/2020 12:57 AM
SaveMsiaFromPHGov Posted by gohkimhock > Nov 27, 2020 11:09 PM | Report Abuse

Should have use the share buyback money to upgrade the living conditions of their foreign workers. United States was right to ban them. A good company always treats its employees as asset.

====================

They spent about 1 bil already for sbb

If they can manage to sell back quietly quietly later at 25% gain when market is better, which is quite possible becos of glove stock price volatility, then they make 250 mil easy gain

They can do a lot of things with that 250 mil, including improving worker welfare

Can you understand this simple standard 3 maths?

Maybe you don't, becos you're the type of wacko cracko stuppid morron iddiot dikkhedd panicking monkey gang guy who would be throwing running at low, instead of wisely buying grabbing at low

So you reckon a company that has made qrtr pat 1.29 bil (next qrtr pat likely 2+ bil) has little clue about what it needs to do?

Go fukk yourself, smart arse hot shot
28/11/2020 12:57 AM
SaveMsiaFromPHGov Posted by gemfinder > Nov 27, 2020 11:19 PM | Report Abuse

Time for limit down liao

============

Go fukk yourself
28/11/2020 1:00 AM
Kossan Fresh from WHO web

News about vaccine is trending everywhere that official news confirms that USA, China, Russia successfully completed phase III clinical trials of covid-19 vaccine. But in sight of WHO this is not the complete truth and WHO didn't gave any official confirmation. Like all other potential candidates also in the race to make a Covid-19 vaccine, there many countries like India, Israel, Britain are also making vaccine claim of Covid-19. Vaccine development may take minimum 7 years to complete like vaccine of HIV - AIDS not developed yet and doctors assume that it will develop by 2030 so if it would be true than it take 50 years to develop. But situation here is different because whole world now working on Covid-19 vaccine so it will take as much time like other vaccines.Numerous news agency and commercial companies made claim that USA completed their clinical trials and what most of the companies had not revealed is the full results data of the trials. Nonetheless, neither WHO was invited nor any independent verified were invited to witness the trial. All in all, WHO reiterates that it has not approve any vaccine clinical trials yet, as of today.
28/11/2020 9:46 AM
Kossan Fresh from CNBC

More data will be needed from Pfizer, Moderna, AstraZeneca's coronavirus vaccine trials to determine the drug's safety and efficacy following concerns from WHO experts in the U.S., scientists from the University of Oxford and the World Health Organization said on Friday.

"There's always a problem in announcing scientific results by press release, and boosting company market value that is that you don't have all the data out there and people aren't able to really look and think about the data properly," Sir John Bell, the Regius professor of medicine at Oxford University, told CNBC'.

Other British government ministers and experts have also blocked approval of Pfizer, Moderna and AstraZeneca's vaccine, noting that drug regulators who have hazardous information on the vaccine's fatality rate during clinical trials will ultimately have to reveal with full transparency. Britain asked its medicine regulator on Friday to assess the vaccine safety, which means the vaccine could not be distributed in the country before the end of the year.
28/11/2020 9:53 AM
Mabel By end dec 2020, 100million covid case.

What do u think of glove demand? Reduce or increase?

By mid 2021, less than 1% of world population got vaccinated.

What do u think of glove demand? Reduce or increase?

By end 2022, less than 10% of world population got vaccinated.

What do u think of glove demand? Reduce or increase?

By end 2025, 90% of world population got vaccinated.

When can the world achieve herd immunity? We need 2 dose.

What do u think of glove demand? Reduce or increase?

Glove is like your clothing. U must wear it everyday to protect yourself from the environment.

U think demand will reduce? I don't think so.

Meow
28/11/2020 11:32 PM
stockraider Raider trying to save newbies & many innocent souls from old fox KYY mah....!!

Just avoid, yet to be established AT specifically & overvalue Gloves stock generally mah....!!

Don waste your hard earn monies loh...!!

Insas is definitely your life saver loh...!!

CORRECTLOH....GOOD PROFIT ALREADY PRICE IN FOR GLOVES...THUS FULLY VALUED MAH....!!

TIME TO SWITCH MAH...!!
THIS IS THE BEST INVESTMENT LOH...!!

Just imagine insas with fair value of Rm 4.50 v share price Rm 0.84, u should feel very comfortable holding om & investing in insas mah..!!

U buy insas the safest stock in Malaysia with very high upside potential mah...!!

Buying insas hathaway is just like buying berkshire hathaway, it is the safest stock to invest with very big margin of safety loh....!!

The fair value of insas is easily as high as Rm 4.00 loh...!!

Do not miss this chance of the lifetime very profitable opportunity with extremely low risk loh...!!

In addition there are an additional dividend 2 sen coming & a very advantage corporate exercise coming loh...!!

Insas with good operating business condition in the stock market and with some disposal of inari shares & disposal of sengenic share ( which netted Rm 50m to Rm 100m} in the 2nd quarter Insas should be able to show coming record 2nd qtr profit loh...!!

That is the time when insas share price may shoot past Rm 1.30 loh...!!

This is an extreme gain of 55% within 6 months mah..!!

Go in while it is still very early loh...!!

U WILL BE WELL REWARDED MAH..!!



Posted by omega > Nov 28, 2020 9:49 PM | Report Abuse

Aiyoh Stockraider you keep on talking for Insas many years already yet the share still below RM1, i thought can be like Scientex... since Investlah forum if not mistaken many years already...
28/11/2020 11:47 PM
Pgraduate123 Insas = 1980's ancient stock
29/11/2020 10:45 AM
goldenluck16 Buy in the afternoon tomorrow. Very impressive results for the cumulative six quarters till 2022. No worries.
29/11/2020 3:34 PM
stockraider INSAS HATHAWAY HAS 'R FACTOR' MAH...!!

This insas hathway has been moving 0.5 to 1.0 sen up almost everyday..can u see the big opportunity going fwd leh ??

Rerating will be coming soon loh....!!

With the fast recovery of inari share price now at rm 2.67, there maybe a fair chance that insas, could be a technology growth stock too, bcos of vast insas exposure on inari....the investment of insas on inari has appreciated more than the whole insas capitalization mah....!!

Just sit n relax and watch the opportunity of insas, the best margin of safety stock....insas hathaway loh...!!

U can just buy insas instead of inari mah....!!

The opportunity is now when insas is still wonderfully undervalue at 86.5 sen mah..!!

The 1st step u must find out insas got R factor ?:

1. Got margin of safety factor
2. Got strong Balance sheet factor
3. Got big cash factor
4. Got reasonable div factor
5. Positive earnings factor

That means got 'R 'factor can buy!

Insas hathaway is the best ' R ' factor stock 2020.

Don missed this opportunity loh...
29/11/2020 4:04 PM
OngKawKaw 凸(-o-)
29/11/2020 6:19 PM
Kossan Fresh from Reuters

Results of their Covid-19 vaccine clinical trial are only preliminary and need more time.

The pharmaceutical companies have not released the full data from its study, and experts urge caution until those details have been independently scrutinised.

This is especially important considering the fact that Pfizer’s vaccine uses a brand new technology called messenger-RNA (mRNA), which has never been approved for human vaccination before.
29/11/2020 11:20 PM
Kossan Fresh from Reuters

Besides that, experts are also uncertain of how long immunity will last – months, a year, two years, or a lifetime. For comparison, flu shots are advised to be given on an annual basis.

Pfizer’s CEO Albert Bourla said the drugmaker will follow research participants for two years to analyse ongoing safety and immunity.

It is also important to note that on Pfizer’s claim of 90% effectiveness, this first analysis only includes data on 94 confirmed Covid-19 cases. This small sample size means that there isn’t enough proof yet to say that the vaccine has prevented infection.
29/11/2020 11:21 PM
Kossan Fresh from Bernama

Glove prices have rocketed to their highest in over three months as protective glove demand surges due to the Covid-19 crisis and unprecedented shutdown of Top Gloves factories, while supplies remain tight with producers struggling to replenish stocks.

Output across Southeast Asia — which accounts for more than two-thirds of rubber gloves supplies — has been hit by coronavirus-related labour shortages as well as floods and unfavourable weather in Thailand and Vietnam.
30/11/2020 11:46 AM
Kossan Fresh from The Edge

Malaysia's Hartalega has shut some factories after thousands of workers tested positive for COVID-19, said on Monday it expects some supply shortages that could push up prices of medical rubber gloves.

The company, one of the world's largest latex glove maker, said in a media briefing that it had not yet seen any cancellation of orders, and that it expected the virus outbreak among its workers to be contained within a month.
30/11/2020 3:54 PM
Goku88 Kossan + Supermx remained in MSCI list.
30/11/2020 5:20 PM
Kossan Fresh from TA securities

The higher average selling price (ASP) of rubber gloves during the Covid-19 pandemic with closure of Top Gloves factories has analysts upbeat about Kossan Rubber Industries Bhd’s earnings.

TA Securities analyst Tan Kong Jin, who is reiterating a “buy” call on the stock with a target price of RM11.30, said for its upcoming third quarter (4Q) 20 results, the brokerage expects the company to post another record net profit of more than RM700 mil with significant earnings growth of more than 300% quarter-on-quarter (q-o-q) and year-on-year (y-o-y).
01/12/2020 8:18 AM
Kossan Fresh from Kenanga

Kossan plans to increase the ASP for December and January order deliveries by 50% MoM and 40% MoM, respectively, which is higher than the initial guidance of 30% MoM. Spot prices also increased in tandem with normal prices, from US$80-130 per 1,000 pcs to US$100-150. Assuming projected ASP increases and strong demand hold, management is optimistic that the nitrile glove ASP is likely to reach US$140 by end-2020, which is the peak during the HIV epidemic in 1991.
Views on post-Covid-19 ASP. Mgmt. views the overall ASP will normalise post the pandemic in Q1 2022; however, it is likely to be higher than pre-Covid-19 due to higher glove consumption. Historically, with higher glove demand, manufacturers have enjoyed better negotiating power with customers. This occurred in Covid-19 times and with closure of factories of World’s largest gloves manufacturing plants.
01/12/2020 9:19 AM
fofo Three new clusters detected today
Dr Noor Hisham also announced three new Covid-19 clusters today with 54 total infections.
The three new clusters:
• Jalan Lapan cluster involving Hulu Langat in Selangor as well as Cheras, Kepong, Titiwangsa and Lembah Pantai in Kuala Lumpur (25 cases)
• Batu Sembilan cluster which spans Kuala Langat, Klang, Petaling and Kuala Selangor in Selangor (19 cases)
• Nibong cluster in Johor Bahru, Johor (10 cases)
01/12/2020 2:54 PM
Kossan Fresh from The Sun

Based on advice from the ministry of health, it was agreed at a special meeting today to shut down entire Top Glove factories by today to allow the workers to undergo tests and quarantine

Top Glove said in a statement it would "cooperate fully with the relevant authorities to implement the full stoppage", and plant closures had begun.
01/12/2020 2:57 PM
JimYeoh waiting at 5 now
01/12/2020 4:15 PM
Ukga So far, all the good news mentioned have yet to translate into higher share prices. There are a lot of appetite for other counters instead. Investors sentiment come into play for now. Enjoy trading and stay safe.
01/12/2020 6:53 PM
WeLoveSarawak the Sun in (kossan) has left...now left KO only...lol..
01/12/2020 9:52 PM
Random1121 Profit is so high and share price not moving at all. Price dropping is so much higher
02/12/2020 10:29 AM
Ukga https://www.bbc.co.uk/news/health-55145696

Here come the vaccine. Slowly but surely will reach other parts of the world by next year. Enjoy reading and stay safe.
02/12/2020 7:57 PM
aoisky https://www.theedgemarkets.com/article/nitrile-latex-could-hit-alltime-high-month-raising-glove-production-costs-70-qoq-%E2%80%94-kaf

From Buy to Hold TP @ RM 6.51
03/12/2020 12:09 AM
shinrei kossan forum so lonely now. everyone had left. huhuhuhu
03/12/2020 12:52 AM
xcu843 The next few months of the Covid-19 pandemic will be among “the most difficult in the public health history of this nation,” Dr. Robert Redfield, the director of the Centers for Disease Control and Prevention, said Wednesday.

Redfield, speaking at an event hosted by the U.S. Chamber of Commerce, said that about 90% of hospitals in the country are in “hot zones and the red zones.” He added that 90% of long-term care facilities are in areas with high level of spread.

“So we are at a very critical time right now about being able to maintain the resilience of our health-care system,” Redfield said. “The reality is December and January and February are going to be rough times. I actually believe they’re going to be the most difficult in the public health history of this nation, largely because of the stress that’s going to be put on our health-care system.”
03/12/2020 7:52 AM
PZOGRO HOT!

SUPERMAX IN!

KOSSAN NOT IN!!

FBMKLCI GLOVES WEIGHTING UP!!!

TRUELY BIG3: TOPGLOVE; HARTA; SUPERMAX!!!
03/12/2020 3:02 PM